ANTX — AN2 Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1880438 ·
Last close
$4.88
Market Cap
$184.15M
52W High
$7.19
52W Low
$1.00
ADV30
230,547
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -8,904,000 | -8,185,000 | 81,676,000 | 44,318,000 | 5,755,000 |
| Mar 2026 | 0 | — | -10,551,000 | -10,028,000 | 87,491,000 | 53,487,000 | 5,732,000 |
| Dec 2025 | 0 | — | -9,316,000 | -8,710,000 | 61,950,000 | 19,941,000 | 8,890,000 |
| Sep 2025 | 0 | — | -10,040,000 | -9,353,000 | 67,235,000 | 18,003,000 | 6,858,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-31,283,000
Investing CF
$27,408,000
Financing CF
$37,377,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.10
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-250,978,000
Inventory
—
Receivables
—
ST Investments
$31,801,000
EBIT TTM
$-37,123,000
Pretax Income TTM
$-34,553,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -38,109,000 | -35,174,000 | 61,950,000 | 8,890,000 | 53,060,000 | -29,834,000 |
| Dec 2024 | 0 | -54,554,000 | -51,321,000 | 92,087,000 | 10,238,000 | 81,849,000 | -49,257,000 |
| Dec 2023 | 0 | -69,635,000 | -64,732,000 | 138,744,000 | 14,043,000 | 124,701,000 | -53,288,000 |
| Dec 2022 | 0 | -42,262,000 | -40,956,000 | 102,560,000 | 7,188,000 | 95,372,000 | -33,462,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MSLE | Satellos Bioscience Inc. | $184.58M | $8.70 | — |
| BCYC | BICYCLE THERAPEUTICS PLC | $186.29M | $3.68 | — |
| ORGO | Organogenesis Holdings Inc. | $181.43M | $1.41 | — |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $181.14M | $1.31 | — |
| PEPG | PepGen Inc. | $179.15M | $2.59 | — |
News headlines (Yahoo Finance, 1h cache)
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
2026-09-28 11:00 · Yahoo
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
2026-09-16 21:33 · Yahoo
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
2026-08-24 11:00 · Yahoo
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
2026-08-11 20:00 · Yahoo
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
2026-06-04 11:00 · Yahoo
Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight
2026-08-31 17:00 · Yahoo
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
2026-08-31 22:00 · Yahoo
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
2026-01-09 17:00 · Yahoo
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
2026-01-09 14:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.